Virtual Library
Start Your Search
Chundong Gu
Author of
-
+
P3.03 - Biology (Not CME Accredited Session) (ID 969)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.03-23 - A Propensity Score Matching Cohort Study on Prognosis of the Diversity of MUC1 Expression in Patients with Lung Adenocarcinoma (ID 13107)
12:00 - 13:30 | Presenting Author(s): Chundong Gu
- Abstract
Background
To probe the expression of MUC1 (Mucin-1) in lung adenocarcinoma tissues, and estimate the relationship between the expression level of MUC1 and prognosis or clinical pathological factors in patients with lung adenocarcinoma simultaneously, so as to establish personal therapeutic strategies and forecast prognosis.
a9ded1e5ce5d75814730bb4caaf49419 Method
A retrospective analysis was originally conducted on 182 lung adenocarcinoma patients who underwent surgical resection collected from July 2007 and September 2010 at the First Affiliated Hospital of Dalian Medical University. None of the patients received neoadjuvant therapy. Each tumor was reevaluated according to the current adenocarcinoma classification based on HE stains. Additional immunohistochemical staining for MUC1(Mucin-1) was used in selected cases. Cox proportional hazard regression model was used for univariate analysis. The confounding parameters were compromised by propensity score matching (PSM).
4c3880bb027f159e801041b1021e88e8 Result
Among 182 patients with lung adenocarcinoma, 107 patients were MUC1 low expressed, 44 patients were MUC1 moderate expressed 33 patients were MUC1 high expressed. We found the expression of MUC1 was significantly different in gender (p=0.014), smoking history (p=0.009), T stage (p=0.019), N stage (p=0.015), clinical stage (p=0.024) and the WHO classification of tumors of the lung adenocarcinoma (p=0.002). But we found all above differences among groups were no significance after PSM. Lung adenocarcinoma patients with high MUC1 expression, poorly differentiated and high pTNM stage had early relapse than the other (P≤0.05), no matter took PSM.
8eea62084ca7e541d918e823422bd82e ConclusionUnivariate analysis of clinical pathologic factors on disease-free survival risk. Clinical Factor
HR
95%CI
P value
Gender
male
1.000
fmale
0.732
0.437-1.226
0.236
Age
≤67
1.000
>67
0.928
0.562 -1.534
0.772
History of smoking
Out
1.000
Without
1.756
0.981 -3.140
0.058
Tumor size
≤2cm
1.000
>2cm
2.100
1.067- 4.135
0.032
Differentiation
Poor
1.000
Moderate
10.929
4.734- 25.232
<0.001
Well
3.151
1.376- 7.218
0.007
T stage
T1
1.000
T2
1.483
0.798- 2.757
0.213
T3
3.831
2.083- 7.048
<0.001
N stage
N0
1.000
N1
2.247
0.879- 5.744
0.091
N2
3.506
2.047- 6.006
<0.001
TNM stage
I
1.000
II
2.310
0.810- 6.591
0.118
III
3.823
2.272- 6.432
<0.001
Pathological subgroups
MIA
1.000
AP
3.414
1.146- 10.174
0.028
PA
1.486
0.600- 3.683
0.392
MPA
2.245
0.918- 5.494
0.076
SOP
5.566
1.116- 27.754
0.036
MU
5.148
0.617- 42.923
0.130
Lep
0.748
0.090- 6.210
0.788
MUC1 expression
Low
1.000
Moderate
1.235
0.604- 2.527
0.563
High
2.289
1.318- 3.974
0.003
MUC1 expression (PSM)
Low
1.000
Moderate
1.289
0.557- 2.985
0.553
High
2.462
1.142- 5.312
0.022
High expression of MUC1 can be a significant independent risk factors for predicting the prognosis of lung adenocarcinoma.
6f8b794f3246b0c1e1780bb4d4d5dc53